Abstract 563: Preclinical development of YL202, a novel HER3-targeting antibody-drug conjugate (ADC) with novel DNA topoisomerase I inhibitor for treatment of solid tumors

Authors: Jian Xu, Qing Zong, Liang Zhu, Qigang Liu, Sasha Stann, Jiaqiang Cai

Published: 2023-04-04

DOI: 10.1158/1538-7445.am2023-563

Source: Full article